Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>Products>This Product
  Products


Culture Kit for human ES/iPS cells

Product Description
Kit contents:
Primate ES Cell Culture Medium, 500ml
Dissociation solution, 30ml
Freezing Medium, 25ml

ReproCELL’s "Culture kit for human ES/iPS cells" was developed through a collaboration between ReproCELL Inc. and Kyoto University. ReproCELL’s "Culture kit for human ES/iPS cells" has been specifically developed for human and ES/iPS cells. The culture kit has been rigorously tested to ensure superior results for culture of human ES/iPS cells. The kit contains three separate components which allow the expansion, passaging and freezing of human ES/iPS cells. This bundle of products is available at a low price with a discount compared to purchasing individual components separately.

Please note that in addition to the materials contained in this kit, you will need to have feeder cells and you will need to coat your culture dish. In addiiton, for culture of cells, FGF-2 is typically added to basic media. ReproCELL is supplying rh FGF-2 (Cat.# RCHEOT002, 003).

Extensively tested for culturing/passaging/freezing human ES/iPS cells
Higher rates of viability at all stages (see individual products for further details)
Lot-to-lot quality control - functionally tested using using human iPS cells.
Lot-to-lot control of other critical criteria including osmolarity, pH, sterility and mycoplasma.
Ready-to-use formulation – no mixing required.
Serum free
Product Culture Kit for human ES/iPS cells
Company ReproCell Products
Price Request a quote
More Information View company product page
Catalog Number RCHECK002
Quantity Unspecified
Company Logo

ReproCell Products
Reprocell Inc KDX Shin-yokohama 381 Bldg 8F 3-8-11, Shin-yokohama, Kohoku-ku, Yokohama Kanagawa 222-0033, Japan

Tel: +81 45-475-3887
Fax: +81 45-474-1006
Email: info_repro@reprocell.com



Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.

Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!